The goal is to predict the response of a targeted cellular / gene therapy in different cancer types and to stratify patients to provide a more individualized cancer treatment with apceth's innovative cell and cell-based gene therapeutics. A reliable biomarker platform will enable oncologists to identify  patients who will most likely benefit from the treatment with apceth's therapeutics, thus establishing a unique and truly personalized therapeutic approach adapted to the needs of each cancer patient.

Since biomarkers for cell and gene therapeutics are not yet available and cancer is still a growing medical problem worldwide, significant demand for an adequate and reliable biomarker platform exists.